U.S. National Library of Medicine
National Center for Biotechnology Information

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Pemetrexed. [Updated 2021 Aug 16].
Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/

Pemetrexed

Revised: August 16, 2021.

CASRN: 137281-23-3



Drug Levels and Effects

Summary of Use during Lactation

Most sources consider breastfeeding to be contraindicated during maternal high-dose antineoplastic drug therapy. The manufacturer recommends that mothers should not to breastfeed during treatment with pemetrexed and for one week after the last dose. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[1] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.[2]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Urbaniak C, McMillan A, Angelini M, et al. Effect of chemotherapy on the microbiota and metabolome of human milk, a case report. Microbiome. 2014;2:24. PubMed PMID: 25061513.
2. Stopenski S, Aslam A, Zhang X, et al. After chemotherapy treatment for maternal cancer during pregnancy, is breastfeeding possible? Breastfeed Med. 2017;12:91–7. PubMed PMID: 28170295.

Substance Identification

Substance Name

Pemetrexed

CAS Registry Number

137281-23-3

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Antimetabolites, Antineoplastic

Antirheumatic Agents

Folic Acid Antagonists

Immunosuppressive Agents